Pharmaresearch Bio Co (XKRX:217950) EV-to-EBIT : 13.16 (As of May. 28, 2024)

View and export this data going back to 2015. Start your Free Trial

What is Pharmaresearch Bio Co EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Pharmaresearch Bio Co's Enterprise Value is ₩97,210 Mil. Pharmaresearch Bio Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was ₩7,388 Mil. Therefore, Pharmaresearch Bio Co's EV-to-EBIT for today is 13.16.

The historical rank and industry rank for Pharmaresearch Bio Co's EV-to-EBIT or its related term are showing as below:

XKRX:217950' s EV-to-EBIT Range Over the Past 10 Years
Min: -133.92 Med: 13.8 Max: 414.11
Current: 13.16

During the past 6 years, the highest EV-to-EBIT of Pharmaresearch Bio Co was 414.11. The lowest was -133.92. And the median was 13.80.

XKRX:217950's EV-to-EBIT is ranked worse than
56% of 425 companies
in the Biotechnology industry
Industry Median: 9.85 vs XKRX:217950: 13.16

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Pharmaresearch Bio Co's Enterprise Value for the quarter that ended in Dec. 2023 was ₩63,496 Mil. Pharmaresearch Bio Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was ₩7,388 Mil. Pharmaresearch Bio Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 11.64%.

Pharmaresearch Bio Co EV-to-EBIT Historical Data

The historical data trend for Pharmaresearch Bio Co's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmaresearch Bio Co EV-to-EBIT Chart

Pharmaresearch Bio Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-73.17

152.94

36.76

13.42

8.59

Pharmaresearch Bio Co Semi-Annual Data
	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
EV-to-EBIT	Get a 7-Day Free Trial			-73.17	152.94	36.76	13.42	8.59

Competitive Comparison of Pharmaresearch Bio Co's EV-to-EBIT

For the Biotechnology subindustry, Pharmaresearch Bio Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharmaresearch Bio Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmaresearch Bio Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Pharmaresearch Bio Co's EV-to-EBIT falls into.

Pharmaresearch Bio Co EV-to-EBIT Calculation

Pharmaresearch Bio Co's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	97209.511	/	7388.331
	=	13.16

Pharmaresearch Bio Co's current Enterprise Value is ₩97,210 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pharmaresearch Bio Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was ₩7,388 Mil.

Pharmaresearch Bio Co (XKRX:217950) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Pharmaresearch Bio Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	7388.331	/	63495.91
	=	11.64 %

Pharmaresearch Bio Co's Enterprise Value for the quarter that ended in Dec. 2023 was ₩63,496 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pharmaresearch Bio Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was ₩7,388 Mil.

Pharmaresearch Bio Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Pharmaresearch Bio Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmaresearch Bio Co (XKRX:217950) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmaresearch Bio Co Ltd (XKRX:217950) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

641-3, Saimdang-ro, Gangwon-do, Gangneung-si, KOR, 13494

Website

http://www.pr-bio.co.kr

Pharmaresearch Bio Co Ltd is a Korea-based biopharmaceutical company. The company is engaged in the research and development, manufacturing, sale, and marketing of biopharmaceutical products. Its product is ReNTox Injections, and Clostridium Botulinum Toxin type A is in pipeline.

Pharmaresearch Bio Co (XKRX:217950) Headlines

No Headlines